Intravascular Imaging-Guided Percutaneous Coronary Intervention in Patients With End-Stage Renal Disease on Maintenance Dialysis by Chia-Pin Lin, MD, Fu-Chih Hsiao, MD, Ying-Chang Tung, MD, Tzyy-Jer Hsu, MD, Shing-Hsien Chou, MD, Yu-Sheng Lin, MD, Shao-Wei Chen, MD, PhD, Pao-Hsien Chu, MD

“…The primary outcome was composite cardiovascular outcomes, including coronary revascularization, cardiovascular death, and acute myocardial infarction. Results: In 2021, IVI was used to guide PCIs in 27% (15,613 of 57,845) of general and 27.5% (1,754 of 6,387) of ESRD patients. …”
Get full text

Sex differences in epigenetic ageing for older people living with HIVResearch in context by Carrie D. Johnston, Alina P.S. Pang, Eugenia L. Siegler, Charlene Thomas, Chelsie O. Burchett, Mia Crowley, Rochelle O'Brien, Lishomwa C. Ndhlovu, Marshall J. Glesby, Michael J. Corley

“…Slower gait (p = 0.0017), greater frailty (p = 0.0074), and history of smoking (p = 0.042) were associated with increased DNAmFitAge. Risk of death was increased in females with PCPhenoAge acceleration over a 5-year timespan compared to men with PCPhenoAge acceleration (p = 0.03). …”
Get full text

Comparative Effects of Glenzocimab and Eptifibatide on Bleeding Severity in 2 Mouse Models of Intracranial Hemorrhage by Sébastien Dupont, Héloïse Lebas, Sabrina Mavouna, Eloïse Pascal, Astride Perrot, Adrien Cogo, Marie‐Charlotte Bourrienne, Carine Farkh, Mialitiana Solo Nomenjanahary, Véronique Ollivier, Fatima Zemali, Bernhard Nieswandt, Stéphane Loyau, Martine Jandrot‐Perrus, Eric Camerer, Jean‐Philippe Desilles, Mikael Mazighi, Yacine Boulaftali, Benoît Ho‐Tin‐Noé

“…Conversely, eptifibatide caused a significant increase in intracranial bleeding in both models, and a drastic increase in death after hyperglycemia‐induced hemorrhagic transformation of cerebral ischemia–reperfusion injury. …”
Get full text

Surgical resection, radiotherapy and percutaneous thermal ablation for treatment of stage 1 non-small cell lung cancer: protocol for a systematic review and network meta-analysis by Arun Chockalingam, Menelaos Konstantinidis, Brandon Koo, John Timothy Moon, Andrew Tran, Sahar Nourouzpour, Emily Lawson, Kathleen Fox, Peiman Habibollahi, Bruno Odisio, Mohammed Loya, Ali Bassir, Nariman Nezami

“…The primary outcomes will include cancer-specific survival, lung disease-free survival, locoregional recurrence, death, toxicity and non-target organ injury. We will also search published and unpublished studies in trial registries and will review references of included studies for possible inclusion. …”
Get full text

High-grade liver injury: outcomes with a trauma surgery–liver surgery collaborative approach by J Wallis Marsh, Abhinav Humar, Jason L Sperry, David A Geller, Deepika Mohan, Timothy R Billiar, Juan Carlos Puyana, Brian Zuckerbraun, Joshua B Brown, Matthew D Neal, Matthew R Rosengart, David Newhouse, Christine Leeper, Andrew B Peitzman, Raquel Forsythe, Rafael G Ramos-Jimenez, Andrew-Paul Deeb, Evelyn I Truong, Sowmya Narayanan, Louis Alarcon, Graciela M Bauza, Vaishali Dixit Schuchert, Gregory Watson, Amit D Tevar

“…Operative mortality attributable to the liver injury was 15.7%. 19.4% of patients failed NOM with one death (1.4%).Conclusion We report an operative mortality of 23.4% for HGLI in a trauma care system characterized by a collaborative approach by trauma surgeons and liver surgeons.Level of evidence III…”
Get full text

Cigarette Smoking Patterns Among Racial and Ethnic Groups With Chronic Lung Diseases During the COVID-19 Pandemic by Vijaya L. Seegulam, MPH, Caretia J. Washington, BS, Parvathy P. Surendran, BPT, Alyssa M. Falise, PhD, MSPH, Diana Gomez-Manjarres, MD, Catalina Lopez-Quintero, MD, MPH, PhD

“…Chronic obstructive pulmonary disease remains the third most prevalent cause of death worldwide, with 90% of chronic obstructive pulmonary disease deaths attributed to combustible cigarette smoking. …”
Get full text

Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study by Prashasti Agrawal, MD, Michael Offin, MD, Victoria Lai, MD, Michelle S. Ginsberg, MD, Prasad S. Adusumilli, MD, FACS, Valerie W. Rusch, MD, Jennifer L. Sauter, MD, Teresa Ho, BS, Phillip Wong, PhD, Marjorie G. Zauderer, MD

“…Galinpepimut-S (GPS), a tetravalent, non–human leukocyte antigen–restricted, heteroclitic WT1–specific peptide vaccine was safe and effective in early phase clinical trials and upregulates T-cell suppressive programmed death-ligand 1 in the tumor microenvironment of other malignancies. …”
Get full text

Prevalence and predictors of permanent pacemaker implantation in patients with aortic stenosis undergoing transcatheter aortic valve implantation: a prospective cohort study by Erlend Eriksen, Ronak Rajani, Sahrai Saeed, Svein Rotevatn, Daanyaal Wasim, Øyvind Bleie, Abukar Mohamed Ali, Erik Jerome Stene Packer, Håvard Keilegavlen

“…The remaining 548 patients were included in the present study.Baseline measures An evaluation of baseline risk factors, 12-lead ECG and echocardiography.Primary outcome measures The need for a new pacemaker implantation ≤30 days following TAVI and all-cause death.Results The mean age was 80.6±6.7 years, and 50% were males. …”
Get full text

Evolving racial/ethnic disparities in AML survival in the novel therapy era by Xin Wang, Phyllis A. Gimotty, Andrew H. Matthews, Ronac Mamtani, Selina M. Luger, Elizabeth O. Hexner, Daria V. Babushok, Shannon R. McCurdy, Noelle V. Frey, Ximena Jordan Bruno, Saar Gill, Mary Ellen Martin, Vikram R. Paralkar, Ivan Maillard, David L. Porter, Alison W. Loren, Alexander E. Perl, Keith W. Pratz, Kelly D. Getz, Catherine Lai

“…In Pre era, NHB had a 22% higher hazard of death than NHW (aHR, 1.22; 95% CI, 1.04-1.43), whereas worse OS was not observed for NHB in Post era (aHR, 0.86; 95% CI, 0.69-1.08; predicted 2-year survival, 45.3% vs 39.9%). …”
Get full text

Effectiveness of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2.2 Infection in Beijing, China, 2022: A Cohabitation Retrospective Cohort Study by Shuaibing Dong, Ying Sun, Zhaomin Feng, Yi Tian, Lei Jia, Xiaoli Wang, Quanyi Wang, Daitao Zhang, Peng Yang

“…There were no cases of severe or critical infection or death. The VE of the primary in preventing BA.2.2 infection, symptoms, and pneumonia was 37.35% (95% CI: 24.00–48.35), 42.36% (95% CI: 28.41–53.60), and 48.35% (95% CI: −5.34–74.67), respectively. …”
Get full text

In vitro antitumor and immunomodulatory activities of 1,2,4-oxadiazole derivatives by Héverton Mendes Araújo, Gabriel Acácio de Moura, Yasmim Mendes Rocha, Cristian Vicson Pinheiro Gomes, Valentina Nascimento e Melo de Oliveira, Ronaldo Nascimento de Oliveira, Larissa Deadame de Figueiredo Nicolete, Emanuel Paula Magalhães, Ramon R.P.P.B. de Menezes, Roberto Nicolete

“…Melanoma is the most aggressive and lethal type of skin cancer, responsible for approximately 60,000 deaths annually. The main strategy for treating melanoma is surgery to completely remove the lesion and its margins. …”
Get full text

Outcome differences in acute vs. acute on chronic heart failure and cardiogenic shock by Tara L. Jones, Michael C. Tan, Vidang Nguyen, Kathleen E. Kearney, Charles C. Maynard, Emily Anderson, Claudius Mahr, James M. McCabe

“…Patients with acute CS were more likely to suffer in‐hospital death (31.4% vs. 9.8%, P < 0.01) despite higher usage of temporary mechanical circulatory support (52% vs. 25%, P < 0.01) compared with patients presenting with acute on chronic HF. …”
Get full text

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherap... by Weiming Liang, Weiming Liang, Zhijing Wang, Zhilong Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Duo Zhang, Chenchen Li

“…ObjectiveTo evaluate the efficacy and safety of programmed cell death protein 1 or its ligand (PD-1/L1) inhibitors as first-line therapy in advanced or metastatic urothelial carcinoma (mUC) who are ineligible for platinum-based chemotherapy.MethodA systematic search was conducted in four databases (Pubmed, Embase, Web of Science, and the Cochrane Library) to find articles that evaluate the effectiveness of first-line PD-1/L1 inhibitors for mUC, from the establishment of the databases to 22 November 2023. …”
Get full text

Multimorbidity latent classes in relation to 11-year mortality, risk factors and health-related quality of life in Malaysia: a prospective health and demographic surveillance syste... by Michelle M. C. Tan, Charlotte Hanlon, Graciela Muniz-Terrera, Tatiana Benaglia, Roshidi Ismail, Devi Mohan, Ann Breeze Joseph Konkoth, Daniel Reidpath, Pedro José M. Rebello Pinho, Pascale Allotey, Zaid Kassim, Matthew Prina, Tin Tin Su

“…This group also exhibited the highest mortality risk over 11 years even after adjustment of confounders (age, sex, ethnicity, education and employment status), with a hazard of death of 1.83 (95% CI 1.44–2.33), followed by the cardiometabolic group (HR 1.42, 95% CI 1.18–1.70) and the musculoskeletal, mobility and sensory disorders group (HR 1.29, 95% CI 1.04–1.59). …”
Get full text

Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study by Fei Han, Hong Pan, Yi Yang, Jianghua Chen, Jing Xue, Lan Lan, Yiting Chen, Pingping Ren, Yaomin Wang, Xin Lei, Jianhang Xu, Xiaochan Chen, Qiankun Zhang, Junni Wang, Nan Shi, Liangliang Chen, Lie Jin

“…Major adverse effects included immunoglobulin deficiency, respiratory tract infection and urinary tract infection. No death occurred.Conclusions The sequential treatment of belimumab or telitacicept following RTX may represent a promising therapeutic approach in the management of refractory lupus nephritis. …”
Get full text

Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care... by Richard D Neal, Kevin Franks, David Torgerson, Rachael L Murray, David R Baldwin, Michael Darby, Henrik Moller, Richard Booton, Una MacLeod, Sam M Janes, Samantha L Quaife, Sebastian Hinde, Matthew EJ Callister, Suzanne Rogerson, Rhian Gabe, Mark Sculpher, Philip AJ Crosbie, Irene Simmonds, Martyn Kennedy, Nazia Ahmed, Ann Cochrane, Mike Messenger, Puvanendran Tharmanathan

“…Introduction Lung cancer is the world’s leading cause of cancer death. Low-dose computed tomography (LDCT) screening reduced lung cancer mortality by 20% in the US National Lung Screening Trial. …”
Get full text

Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study by Christiaan F.J. Antonides, Felix Schoenrath, Theo M.M.H. deBy, Rahatullah Muslem, Kevin Veen, Yunus C. Yalcin, Ivan Netuka, Jan Gummert, Evgenij V. Potapov, Bart Meyns, Mustafa Özbaran, David Schibilsky, Kadir Caliskan, the EUROMACS investigators

“…A Kaplan–Meier analysis for freedom of the composite endpoint of death, heart transplantation, LVAD reimplantion, or heart failure (HF) relapse was conducted. …”
Get full text

A Multicenter, Prospective Study of a New Fully Covered Expandable Metal Biliary Stent for the Palliative Treatment of Malignant Bile Duct Obstruction by Bret T. Petersen, Michel Kahaleh, Richard A. Kozarek, David Loren, Kapil Gupta, Thomas Kowalski, Martin Freeman, Yang K. Chen, Malcolm S. Branch, Steven Edmundowicz, Michael Gluck, Kenneth Binmoeller, Todd H. Baron, Raj J. Shah, Timothy Kinney, William Ross, Paul Jowell, David Carr-Locke

“…Main outcome measurements included (1) absence of stent occlusion within six months or until death, whichever occurred first and (2) technical success, need for reintervention, bilirubin levels, stent patency, time to stent occlusion, and adverse events. …”
Get full text

Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study by André Aires Fernandes, André Aires Fernandes, Ana Lídia Neves, Ana Lídia Neves, Daniela Ferro, Daniela Ferro, Mafalda Seabra, Mafalda Seabra, Teresa Mendonça, Ricardo Soares dos Reis, Ricardo Soares dos Reis, Maria José Sá, Joana Guimarães, Joana Guimarães, Pedro Abreu, Pedro Abreu

“…During this period, serious adverse events were observed in 9 patients, including SARS-CoV-2 infection (resulting in one death), urinary tract infection, febrile neutropenia, severe diarrhea, and acute hepatitis. …”
Get full text

Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade by Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima

“…Anti-thyroglobulin antibodies (TgAb) and/or anti-thyroid peroxidase antibodies (TPOAb) positivity at baseline is a risk marker for thyroid immune-related adverse events (thyroid-irAEs) in anti-programmed cell death-1 antibody (PD-1-Ab) treatment; however, it is unknown if TgAb and TPOAb titers are associated with clinical characteristics of thyroid-irAEs. …”
Get full text